Document Detail

Understanding the difficulty.
MedLine Citation:
PMID:  23538261     Owner:  NLM     Status:  In-Data-Review    
Safely administering infusional therapies is my primary role as an oncology nurse working in the outpatient setting. Included in this function are many supportive measures to ensure that each patient has the optimal chance not only to benefit from this encounter, but to experience the least harm. Last September, a 69-year-old retired men's clothing designer named A.C., who had metastatic colon cancer diagnosed in 2006, was scheduled in my clinic to receive IV hydration. This was necessitated by intractable diarrhea presumed to be a result of previous chemotherapy drugs, which had since been discontinued. He reported emptying his colostomy of two to three liters of liquid stool per day and had recently been discharged from a four-week inpatient stay for the same reason. He was still receiving single-agent IV immunotherapy every two weeks, which, as indicated on computed tomography scan, had kept his disease stable; however, A.C. suffered daily with the effects of prolonged, unrelenting diarrhea. Of note, A.C. was a Medicare recipient and also maintained long-term disability that provided a home health attendant (HHA) for both he and his wife, who had multiple sclerosis.
Elaine B Llanos
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical journal of oncology nursing     Volume:  17     ISSN:  1538-067X     ISO Abbreviation:  Clin J Oncol Nurs     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9705336     Medline TA:  Clin J Oncol Nurs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  213-4     Citation Subset:  N    
Memorial Sloan-Kettering Cancer Center, New York, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.
Next Document:  Chemobrain in underserved african american breast cancer survivors.